All In Biotech

Free tool

FAERS Monitor: Ameluz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208081 or its brand name (Ameluz, Aminolevulinic Acid Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

292

Serious

112

38% of reports

Hospitalization

29

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use74
  • application site pain59
  • application site erythema50
  • hypotension30
  • drug ineffective17
  • application site swelling16
  • product odour abnormal15
  • pain12
  • product colour issue11
  • application site pustules10
  • application site vesicles10
  • erythema10
  • hypersensitivity10
  • nausea10
  • vomiting9

Reports by year received

View as table
YearReports
20131
20142
20152
20162
201725
201826
201924
202018
202130
202230
202342
202435
202532
202623

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,867 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site pustulesSignal102031.11094.917,810
application site swellingSignal16232.0143.93,442
application site painSignal59193.4154.011,086
product colour issueSignal11154.786.61,527
application site erythemaSignal50137.7106.96,644
application site vesiclesSignal10111.260.5984
product odour abnormalSignal15103.363.11,418
hypotensionSignal3010.87.7259
off label useSignal746.15.0323
hypersensitivitySignal103.92.119
erythemaSignal103.51.916
pain121.40.81
vomiting91.40.71
drug ineffective170.90.60
nausea100.90.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.